Biochemical features, molecular biology and clinical relevance of the human 15-domain serine proteinase inhibitor LEKTI.
Based on the isolation of a 55 amino acid peptide from human hemofiltrate, we cloned the cDNA for a novel human 15-domain serine proteinase inhibitor termed LEKTI. A trypsin-inhibiting activity was demonstrated for three different domains. High levels of expression of the corresponding gene were detected in oral mucosa, followed by the tonsils, parathyroid glands, thymus, and trachea. Hovnanian and coworkers recently found that certain mutations within the LEKTI gene are linked to the severe congenital disease Netherton syndrome and atopic manifestations (including asthma). Thus, a future therapeutic use of LEKTI is conceivable.
Walden
Michael
M
IPF Pharmaceuticals GmbH, Hannover, Germany.
Kreutzmann
Peter
P
Drögemüller
Katrin
K
John
Harald
H
Forssmann
Wolf-Georg
WG
Hans-Jürgen
Mägert
M
D002352:Carrier Proteins; D006801:Humans; D008967:Molecular Biology; D009154:Mutation; D017434:Protein Structure, Tertiary; D053491:Proteinase Inhibitory Proteins, Secretory; D000074163:Serine Peptidase Inhibitor Kazal-Type 5; D015842:Serine Proteinase Inhibitors / Q000235:genetics* / Q000378:metabolism / Q000502:physiology*; D014018:Tissue Distribution
D002352:Carrier Proteins; D053491:Proteinase Inhibitory Proteins, Secretory; C120650:SPINK5 protein, human; D000074163:Serine Peptidase Inhibitor Kazal-Type 5; D015842:Serine Proteinase Inhibitors